GlassScriptPhysician profile
Drew Ernest Polson
NPI 1700084829
$1,414.34
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.69 · 2022: $400 · 2023: $481 · 2024: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $947 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $946.78 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $172.23 | 2022-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $140.31 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $132.42 | 2022-2024 | Mounjaro, Jardiance |
| Antares Pharma, INC. | $118.28 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Abbvie INC. | $107.81 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.30 | 2019-2024 | Jardiance, Synjardy |
| Exact Sciences Corporation | $98.54 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $81.61 | 2022-2024 | |
| Amgen INC. | $68.91 | 2023-2024 | Repatha, Otezla |
| Abbott Laboratories | $63.73 | 2022-2024 | Proclaim |
| Novo Nordisk INC | $58.67 | 2019-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $56.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.46 | 2022-2023 | Xifaxan |
| Halozyme INC | $38.39 | 2023 | |
| Janssen Pharmaceuticals, INC | $23.70 | 2019-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $23.10 | 2024 | Rexulti |
| Tris Pharma INC | $17.66 | 2022 | |
| Corium, LLC | $16.53 | 2023 | Azstarys |
| Novartis Pharmaceuticals Corporation | $16.44 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.41 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $12.81 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Polson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.